Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Operating Income (2023 - 2025)

Historic Operating Income for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.2 million.

  • BioLineRx's Operating Income rose 5903.1% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year increase of 6721.37%. This contributed to the annual value of -$20.4 million for FY2024, which is 5893.27% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Operating Income is -$2.2 million, which was up 5903.1% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Operating Income ranged from a high of -$2.2 million in Q3 2025 and a low of -$18.6 million during Q4 2023
  • For the 3-year period, BioLineRx's Operating Income averaged around -$7.0 million, with its median value being -$5.4 million (2024).
  • The largest annual percentage gain for BioLineRx's Operating Income in the last 5 years was 7616.07% (2024), contrasted with its biggest fall of 4177.51% (2024).
  • BioLineRx's Operating Income (Quarter) stood at -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then soared by 50.14% to -$2.2 million in 2025.
  • Its Operating Income was -$2.2 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$2.4 million in Q1 2025.